USPTO serial 79289877
LUNAC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 6, 2021
- Examiner
- TRATOS, MARK STEVEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LUNAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew L. Frisbee
Matthew L. Frisbee Leason Ellis LLPOne North Lexington Ave., Suite 1200White Plains, NY 10601United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations, namely pharmaceutical preparations for the treatment of blood disorders, blood clots and to prevent blood coagulation; pharmaceuticals, namely pharmaceutical preparations for the treatment of blood disorders, blood clots and to prevent blood coagulation; medicines, namely pharmaceutical preparations for the treatment of blood disorders; therapeutic medicines and pharmaceuticals, namely pharmaceutical preparations for the treatment of blood disorders; medical diagnostic products, namely diagnostic preparations for medical purposes; anticoagulants; anticoagulants for the treatment of medical conditions; anticoagulants for the treatment of thrombosis and blood clots; anticoagulants for use in the discovery, preclinical and clinical development of therapeutic products and medical diagnostic products; medicines and pharmaceuticals for use in the discovery, preclinical and clinical development of therapeutic products and medical diagnostic products, namely anticoagulants | ACTIVE | — |
| 040 | custom manufacture of chemicals, medicines, pharmaceuticals and anticoagulants; custom manufacture of therapeutic products and medical diagnostic products in the nature of pharmaceuticals for the treatment of blood disorders, blood clots and to prevent blood coagulation; consultancy, advisory and information in connection with all of the aforementioned services, namely, providing advisory services regarding the custom manufacture of pharmaceuticals for others | ACTIVE | — |
| 042 | Scientific and technological services, namely, providing scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation; research and design in relation to science, technology, pharmaceuticals, medicine, blood, thrombosis and anticoagulants, namely, providing scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation; preparation of scientific reports on anticoagulants for medical and veterinary purposes; engineering of medicines and pharmaceuticals; bimolecular engineering of anticoagulants, namely, the manipulation of oral small molecules for use as anticoagulants; engineering of anticoagulants; engineering of medicines and pharmaceuticals for the treatment of thrombosis and blood clotting; scientific services relating to the discovery, preclinical and clinical development of therapeutic and medical diagnostic products, namely, providing scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation; consultancy, advisory and information in connection with all of the aforementioned services, namely, advising regarding scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Lunac Therapeutics Limited
- Other trademarks owned by Lunac Therapeutics Limited
- Other trademarks owned by Lunac Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named LUNAC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 6, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 17, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 29, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 9, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 9, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 6, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 6, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 20, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 20, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 18, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 31, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 31, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 31, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 12, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 11, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 11, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 11, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 11, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 25, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 24, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 24, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 6, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 2, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 28, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 28, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 27, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 24, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 24, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |